ArticleFrontiers in endocrinology2025
Management of type I gastric-neuroendocrine tumors: the less the better?
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Type I gastric neuroendocrine tumors (gNETs) are known for their favorable prognosis. We aimed to present a real-life experience at a tertiary referral center. Materials and methods: Retrospective analysis of patients diagnosed with type I gNETs at our Institution between 2014 and 2024. Results: A total of 36 lesions were identified in 23 patients, with a median tumor size of 7 mm (range 2-20 mm). There were 29 out of 36 lesions that were G1, and 7 were G2. In 13 cases, endoscopic ultrasound (EUS) was performed prior to resection, revealing lymph node involvement in one 20-mm G1 lesion that required surgery. A 15-mm G2 lesion underwent surgery. In the remaining 34 lesions, endoscopic resection was performed: forceps in 5, cold-snare polypectomy in 4, hot-EMR in 22, EMR-cap in 1, ESD in 1, hybrid-ESD in 1. Among those, one 5-mm G2 lesion, previously removed via simple polypectomy, required surgery due to the 14.5% Ki-67 index. The median follow-up was 14 months (range 1-120), with 10 cases of local recurrence in 6 patients, median tumor size 3 mm (range 2-8 mm), all G1. In three cases, endoscopic surveillance was indicated; seven NETs underwent endoscopic resection (three forceps, two EMR-cap, two EMR), with EUS being performed in four cases with negative results. No local/distant metastases nor tumor-related deaths occurred. Conclusions: Present data confirm an indolent behavior for type I gNETs. Preoperative EUS staging led to a change in the management in one case, which highlights the need of dedicated studies to identify predictive factors to stratify risk and plan the management of these neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.